Nasdaq
$14.36▼ 0.28%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $4.91BShares out 3.400M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
12- 10.16Pre-market26.10.16 22:008-KKey event#●●●#●●●
Erasca, Inc.
Erasca is realigning its leadership structure to support the development and commercialization of its RAS-targeting programs, resulting in the termination of Chief Operating Officer Nicholas Chetwyn effective November 2, 2026. This move is intended to streamline the company's reporting structure and enhance operational efficiency.…more
$14.36-0.28%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.15Regular26.10.16 01:18144Ownership
Erasca, Inc.
The Erasca Foundation has filed an SEC Form 144 regarding the proposed sale of shares in Erasca, Inc. This filing indicates the intent of an insider or major shareholder to sell their holdings in the market.…more
$14.36-0.28%vs prev closeView filingShare - 9.15After-hours26.09.16 05:46144Ownership
Erasca, Inc.
Erasca Foundation, an insider of Erasca, Inc., has filed an SEC Form 144 to report a proposed sale of company shares. This filing represents a standard notification of an insider's plan to dispose of equity holdings.…more
$14.36-0.28%vs prev closeView filingShare
11 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 9.8Pre-market26.09.08 20:00#●●●#●●●
Erasca to Present at Morgan Stanley Global Healthcare Conference
Erasca announced its participation in the 24th Annual Morgan Stanley Global Healthcare Conference to engage with investors. This event is a standard corporate presentation and does not provide immediate material impact on the stock.…more
$14.36-0.28%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 8.24Pre-market26.08.24 21:00
●●●●●●●● ●●●●● ●●●●●●
Erasca's ERAS-0015 has been granted FDA Fast Track designation for the treatment of metastatic pancreatic adenocarcinoma, potentially accelerating its development. The company plans to leverage encouraging Phase 1 clinical data to advance toward registrational trials in pancreatic and lung cancers.…more
$14.36-0.28%vs prev close - 8.11After-hours26.08.12 05:01
●●●●●●●● ●●●●● ●●●●●●
에라스카는 주요 파이프라인 ERAS-0015의 긍정적인 임상 데이터를 발표하며 췌장암 및 폐암 대상의 등록 임상 가속화를 예고했습니다. 최근 대규모 유상증자를 통해 확보한 자금을 바탕으로 연구개발 동력을 강화하고 있습니다.…more
$14.36-0.28%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report